BioMarin Pharmaceutical Inc. (BMRN) PT Cut to $77 at Nomura as Risks Threaten 1/3 of Revenue
Tweet Send to a Friend
Nomura/Instinet analyst Christopher Marai lowered the price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $77.00 (from $93.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
